WJOG5108L_2B | R Documentation |
Kaplan-Meier digitized data from WJOG5108L, figure 2B (PMID 27022112). A reported sample size of 561 for a primary endpoint of PFS in lung cancer.
WJOG5108L_2B
A data frame of 559 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (erlotinib, gefitinib) | |
Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016; 34: 3248–57.
summary(WJOG5108L_2B)
kmplot(WJOG5108L_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.